Menofree
Menofree, licence 80060022: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Golden Formulas Menofree, Golden Rules Menofree, Seven Medallion Menofree
- Licence holder
- Golden Rules Medical Inc.
- NPN or DIN-HM
- 80060022
- Status
- Active licence
- Licence date
- 17 April 2015
- Revision date
- 14 June 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Actaea racemosa Source : Rhizome | 54.0 milligramme | Not calculated |
| Angelica sinensis Source : Racine | 50.0 milligramme | Not calculated |
| Glycine max Source : Graine(s) Potency : 11.0 mg ÉAI Isoflavones | 55.0 milligramme | Not calculated |
| Glycyrrhiza glabra Source : Racine et stolon | 50.0 milligramme | Not calculated |
| Vitex agnus-castus Source : Fruit | 34.0 milligramme | Not calculated |
Non-medicinal ingredients
Maltodextrine, Gélatine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 1.0 Capsule | 1.0 Jour(s) |
Uses authorised in Canada
Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flashes. Used in Herbal Medicine to help relieve premenstrual symptoms.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are breastfeeding. Consult a health care practitioner prior to use if you have a liver disorder or develop symptoms of liver trouble. Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy.
- Contre-indications
If you have allergy/hypersensitivity to members of the Apiaceae/Umbelliferae family (anise, caraway, carrot, celery, dill, parsley), do not use this product. If you have diarrhoea or haemorrhagic diseases, do not use this product. If you have hypermenorrhoea/ profuse menstrual flow/ heavy periods, do not use this product. Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician.
- Effets indésirables connus
If you experience breast pain, discomfort and/or tenderness, discontinue use and consult a health care practitioner.
Source
Official Health Canada record, licence 80060022
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.